Benefits of Dexmedetomidine in Management of Post-ECT Agitation. Issue 3 (September 2017)

• Record Type: Journal Article
• Authors: Narang, Puneet; Ianovich, Francesca; Sarai, Simrat Kaur; Lippmann, Steven
• Is Part Of: Journal of ECT. Volume 33:Issue 3(2017:Sep.)
• Publication Date: 2017-09
• Subjects: electroconvulsive therapy -- dexmedetomidine -- postictal agitation -- agitation; Electroconvulsive therapy -- Periodicals; Shock therapy -- Periodicals; Electroconvulsive Therapy -- Periodicals; Electroconvulsive therapy; Shock therapy; Periodicals; Periodicals; Electronic journals; 616.89122
• DOI: 10.1097/YCT.0000000000000393
• Languages: English
• ISSNs: 1095-0680

Abstract

Abstract : Abstract: Electroconvulsive therapy (ECT) is an intervention for patients with a variety of psychiatric conditions. Occasionally, people exhibit dangerous degrees of agitation after this treatment, and some do not respond well to conventional pharmacotherapies. Dexmedetomidine is a central α-2 agonist that can induce significantly calmative effects in persons with post-ECT agitation. The indication for it is in calming individuals with acute and/or recurrent posttreatment agitation. Dexmedetomidine is safe and effective when infused just before, or postictally, at ECT sessions.